ICON (ICLR) vs Personalis (PSNL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Personalis (PSNL) has outperformed ICON (ICLR) over the past year, gaining 85.8% versus a loss of 12.5%. Over five years, PSNL leads with a -19.8% price change compared with -40.3% for ICLR. ICON is the larger company by market cap ($12.67 billion vs $1.71 billion), about 7.4 times the size.
ICON converts more of its revenue into profit, with a net margin of 2.8% versus -116.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ICLR | PSNL |
|---|---|---|
| Share price | $164.17 | $16.00 |
| Market cap | $12.67B | $1.71B |
| 1-day change | -0.20% | -0.37% |
| YTD return | -9.91% | +101.01% |
| 1-year return | -12.54% | +85.83% |
| 5-year return | -40.31% | -19.76% |
| P/E ratio (TTM) | 172.81 | — |
| Forward P/E | 13.92 | — |
| EPS (TTM) | $0.95 | $-1.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $8.25B | $69.65M |
| Revenue growth (YoY) | +0.76% | -17.69% |
| Net income (latest FY) | $229.34M | $-81.27M |
| Gross margin | 26.37% | 22.65% |
| Operating margin | 5.37% | -126.43% |
| Net margin | 2.78% | -116.69% |
| 52-week high | $203.91 | $18.89 |
| 52-week low | $66.57 | $4.96 |
| Distance from 52-week high | -19.49% | -15.30% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +12.33% | -5.19% |
| Average volume | 822.57K | 3.53M |
| Shares outstanding | 77.15M | 106.80M |
| Employees | 40,200 | 259 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ICON is about 7.4 times larger than Personalis by market value ($12.67B vs $1.71B).
- PSNL has outperformed ICLR by 98.4 percentage points over the past year.
- ICON is more profitable, keeping 2.8 cents of every revenue dollar as net income versus -116.7 cents for Personalis.
- ICON grew revenue faster in its latest fiscal year (+0.76% vs -17.69%).
About ICON
ICLR stock →ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 40,200 employees
About Personalis
PSNL stock →Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.
Health Care · Medical Specialities · 259 employees
ICLR vs PSNL FAQ
Which is bigger, ICON or Personalis?
ICON (ICLR) is larger, with a market capitalization of $12.67B compared with $1.71B for Personalis (PSNL).
Which stock has performed better over the past year, ICLR or PSNL?
PSNL returned +85.83% over the past 12 months, compared with -12.54% for ICLR (price return, excluding dividends). Past performance does not predict future results.
Are ICON and Personalis in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Commercial Physical & Biological Resarch for ICON and Medical Specialities for Personalis.